Ascletis Pharma Inc.

About Us
Corporate Overview Management Team Board of Directors Contact Us
Our Focus
Metabolic Diseases Immune Diseases Exploratory Indications
Pipeline
Pipeline Clinical Trials
Partnership
Investors
Financials & Filing Upcoming Events Corporate presentation SCIENTIFIC PRESENTATIONS
News
Careers

Investors

Financials & Filing
Upcoming Events
Corporate presentation
SCIENTIFIC PRESENTATIONS

2026
2025
2024
2023
2022
2021
2020
2019
2018

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021
2021-12-03
Announcement - Inside Information - Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/GANOVO® Regimen, an All-Oral Direct Anti-HCV Therapy and Resumption of Trading
2021-12-03
Trading Halt
2021-12-03
Next Day Disclosure Returns - Share Buyback
2021-12-02
Next Day Disclosure Returns - Share Buyback
2021-12-01
Next Day Disclosure Returns - Share Buyback
2021-11-30
Next Day Disclosure Returns - Share Buyback
2021-11-29
Next Day Disclosure Returns - Share Buyback
2021-11-26
Next Day Disclosure Returns - Share Buyback
2021-11-25
Next Day Disclosure Returns - Share Buyback
2021-11-24

3

© 2018 Ascletis Pharma Inc.

All Rights Reserved

contact

pr@ascletis.com
bd@ascletis.com

hr@ascletis.com
clinicaltrials@ascletis.com

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1